CD79A and COVID-19: Some studies report an increase of salivary IgA after 8 mo from the BNT162b2-booster vaccination (25), while others show a decline in nasal IgA response 9 mo after hospitalization for COVID-19 and a minimal impact of subsequent vaccination (26).